Enliven Therapeutics (NASDAQ:ELVN) just reported results for the second quarter of 2024.
- Enliven Therapeutics reported earnings per share of -41 cents. This was above the analyst estimate for EPS of -55 cents.
- The company did not report any revenue for the quarter.